[go: up one dir, main page]

MX9303977A - PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMPROVEMENT OF THE TRAINING OF A PHARMACOLOGICALLY ACTIVE SUBSTANCE THROUGH THE MUCOUS MEMBRANES OF AN ANIMAL. - Google Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMPROVEMENT OF THE TRAINING OF A PHARMACOLOGICALLY ACTIVE SUBSTANCE THROUGH THE MUCOUS MEMBRANES OF AN ANIMAL.

Info

Publication number
MX9303977A
MX9303977A MX9303977A MX9303977A MX9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A
Authority
MX
Mexico
Prior art keywords
animal
improvement
pharmacologically active
mucous membranes
training
Prior art date
Application number
MX9303977A
Other languages
Spanish (es)
Inventor
Charlotte A Kensil
Sean Soltysik
Dante J Marciani
Original Assignee
Cambridge Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotech Corp filed Critical Cambridge Biotech Corp
Publication of MX9303977A publication Critical patent/MX9303977A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los métodos para el mejoramiento del transporte de substancias farmacológicamente activas a través de las membranas mucosas de un animal, mediante la administración de composiciones farmacéuticas que comprenden saponinas modificadas o fracciones de las mismas, obtenibles mediante modificación de un extracto de Quillaja saponaria crudo, o mediante modificación de saponinas purificadas obtenibles de un extracto crudo de Quillaja saponaria. También se describen las saponinas modificadas que tienen irritabilidad reducida, en donde la porción de ácido graso se elimina mediante hidrólisis o se reduce el grupo aldehído. También se describen las composiciones farmacéuticas que comprenden las saponinas modificadas de la invención.Methods are described for the improvement of the transport of pharmacologically active substances through the mucous membranes of an animal, by the administration of pharmaceutical compositions comprising modified saponins or fractions thereof, obtainable by modification of a crude Quillaja saponaria extract, or by modifying purified saponins obtainable from a raw Quillaja saponaria extract. Modified saponins having reduced irritability are also described, wherein the fatty acid portion is removed by hydrolysis or the aldehyde group is reduced. Pharmaceutical compositions comprising the modified saponins of the invention are also described.

MX9303977A 1992-07-02 1993-07-01 PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMPROVEMENT OF THE TRAINING OF A PHARMACOLOGICALLY ACTIVE SUBSTANCE THROUGH THE MUCOUS MEMBRANES OF AN ANIMAL. MX9303977A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/906,870 US5273965A (en) 1992-07-02 1992-07-02 Methods for enhancing drug delivery with modified saponins

Publications (1)

Publication Number Publication Date
MX9303977A true MX9303977A (en) 1994-04-29

Family

ID=25423119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303977A MX9303977A (en) 1992-07-02 1993-07-01 PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMPROVEMENT OF THE TRAINING OF A PHARMACOLOGICALLY ACTIVE SUBSTANCE THROUGH THE MUCOUS MEMBRANES OF AN ANIMAL.

Country Status (11)

Country Link
US (2) US5273965A (en)
EP (1) EP0658111B1 (en)
JP (1) JP3684370B2 (en)
AU (1) AU687005B2 (en)
BR (1) BR9306594A (en)
CA (1) CA2139437A1 (en)
DE (1) DE69326772T2 (en)
FI (1) FI946173L (en)
HU (1) HUT73814A (en)
MX (1) MX9303977A (en)
WO (1) WO1994001118A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
US5780444A (en) * 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
ES2290074T3 (en) 1993-07-19 2008-02-16 Angiotech Pharmaceuticals, Inc. ANTI-ANGIOGENIC COMPOSITIONS CONTAINING TAXOL AND A NON-BIODEGRADABLE VEHICLE AND ITS USE.
KR970701043A (en) * 1994-02-25 1997-03-17 데이비드 키즈키스 ANTI-INFLAMMATORY AND INFECTION PROTECTIVE EFFECTS OF SESAMIN-BASED LIGNANS
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
AU773686B2 (en) * 1996-02-21 2004-06-03 Intarcia Therapeutics, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
AU2275697A (en) * 1996-02-21 1997-09-10 Matrix Pharmaceutical, Inc. Use of cell membrane permeants in the treatment of cellular proliferative disea ses
AU730230B2 (en) * 1996-12-02 2001-03-01 Aquila Biopharmaceuticals, Inc. Novel saponin compositions and uses thereof
US6471943B1 (en) 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (en) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Analogs of triterpene saponin endowed with adjuvant and immunostimulatory activity
US8765177B2 (en) 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
US20070059327A2 (en) * 1998-01-15 2007-03-15 Wyeth Streptococcus equi compositions and methods of use
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
CA2328946C (en) 1998-04-17 2008-02-12 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for recovery and purification of saponins and sapogenins from quinoa (chenopodium quinoa)
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
ATE315405T1 (en) 1998-08-10 2006-02-15 Antigenics Inc CPG COMPOSITIONS, SAPONIN ADJUVANTS AND METHODS OF USE THEREOF
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
ES2311478T3 (en) * 1999-11-19 2009-02-16 Csl Limited VACCINE COMPOSITIONS AGAINST HCV.
CZ304942B6 (en) * 2000-03-31 2015-02-04 Purdue Research Foundation Medicament for increasing specific elimination of tumor cell population and pharmaceutical composition containing phosphate-FITC conjugate or phosphate-dinitrophenyl
JP2004505894A (en) 2000-06-02 2004-02-26 ユニバーシティー　オブ　コネティカット　ヘルス　センター Complex of α (2) macroglobulin and antigen molecule for immunotherapy
WO2002011669A2 (en) * 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
ATE409495T1 (en) 2001-04-04 2008-10-15 Nordic Vaccine Technology As POLYNUCLEOTIDE BINDING COMPLEXES THAT CONTAIN STEROLS AND SAPONINS
KR20040015234A (en) * 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 Treatment and diagnosis of macrophage mediated disease
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
DK1434603T3 (en) * 2001-09-28 2010-04-26 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU2002357359B2 (en) * 2001-12-21 2009-01-08 Csl Limited Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004092329A2 (en) * 2003-04-08 2004-10-28 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
BRPI0507680A (en) * 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc therapeutic calcium phosphate particles and methods of manufacture and use thereof
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20080287662A1 (en) * 2005-06-22 2008-11-20 Zeev Wiesman Balanites Aegyptiaca Saponins and Uses Thereof
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
CA2692221A1 (en) * 2007-06-27 2008-12-31 Coloplast A/S Treatment of urinary tract infections with a mixture of saponin and an antibiotic
EP2222328A4 (en) * 2007-11-15 2013-06-05 Endocyte Inc Method of administering conjugates
CN102946900A (en) 2010-03-11 2013-02-27 免疫设计公司 Vaccines for pandemic influenza
US9332776B1 (en) 2010-09-27 2016-05-10 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
US8939388B1 (en) 2010-09-27 2015-01-27 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
SG192759A1 (en) 2011-02-15 2013-09-30 Immune Design Corp Methods for enhancing immunogen specific immune responses by vectored vaccines
JP2014515597A (en) 2011-03-04 2014-07-03 インターナショナル フレーバーズ アンド フラグランシズ インコーポレイテッド Spray-dried composition capable of retaining volatile compounds and method for producing the composition
US20130022728A1 (en) * 2011-03-04 2013-01-24 International Flavor & Fragrances Inc. Spray-Dried Compositions Capable of Retaining Volatile Compounds and Methods of Producing the Same
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6619648B2 (en) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Vaccine for HSV-2
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
MX2016009464A (en) 2014-01-21 2017-01-16 Immune Design Corp Compositions for use in the treatment of allergic conditions.
EP3104878B1 (en) 2014-02-14 2019-05-22 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2016011083A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US10155234B1 (en) 2017-08-04 2018-12-18 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10486173B2 (en) 2017-08-04 2019-11-26 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9993787B1 (en) 2017-08-04 2018-06-12 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9861945B1 (en) 2017-08-04 2018-01-09 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
CA3071115C (en) 2017-08-04 2022-06-21 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10569244B2 (en) 2018-04-28 2020-02-25 ZoomEssence, Inc. Low temperature spray drying of carrier-free compositions
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
WO2021014026A2 (en) * 2019-07-25 2021-01-28 Sapreme Technologies B.V. Bioactive saponin linked to a functional moiety
KR20220149505A (en) 2019-12-03 2022-11-08 누보젠 인코포레이티드 tumor cell vaccine
US20230117744A1 (en) 2020-03-23 2023-04-20 Loyola University Of Chicago Coronavirus vaccines compositions and method of using same
EP4171644A2 (en) * 2020-06-24 2023-05-03 Sapreme Technologies B.V. Saponin derivatives for use in medicine
IL299356A (en) * 2020-06-24 2023-02-01 Sapreme Tech Bv hydrazone derivatives of saponin
EP4236995A2 (en) 2020-11-02 2023-09-06 Neuvogen, Inc. Tumor cell vaccines
CN113480985A (en) * 2021-07-07 2021-10-08 东营煜煌能源技术有限公司 Preparation method and application of micro-nano expanded micelle elastic particle oil displacement emulsion

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD160763A3 (en) * 1978-06-05 1984-03-07 Loeffler Friedrich Inst PROCESS FOR THE PRODUCTION OF CONCENTRATE VACCINES
FR2456116A1 (en) * 1979-05-11 1980-12-05 Sarget Lab NOVEL TRITERPENIC SAPONIN DERIVED FROM CAULOPHYLLOGENIN AND ITS THERAPEUTIC APPLICATIONS
GB2064320B (en) * 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPS62126135A (en) * 1985-11-25 1987-06-08 Sumitomo Pharmaceut Co Ltd GRF preparation for nasal administration
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5166139A (en) * 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5118676A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5118692A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhances for transdermal delivery of systemic agents
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye

Also Published As

Publication number Publication date
AU687005B2 (en) 1998-02-19
JPH07509440A (en) 1995-10-19
WO1994001118A1 (en) 1994-01-20
DE69326772D1 (en) 1999-11-18
EP0658111A4 (en) 1996-02-07
JP3684370B2 (en) 2005-08-17
FI946173L (en) 1995-02-15
US5273965A (en) 1993-12-28
US5443829A (en) 1995-08-22
EP0658111B1 (en) 1999-10-13
HUT73814A (en) 1996-09-30
EP0658111A1 (en) 1995-06-21
BR9306594A (en) 1998-12-08
AU4664993A (en) 1994-01-31
CA2139437A1 (en) 1994-01-20
FI946173A0 (en) 1994-12-30
DE69326772T2 (en) 2000-06-29
HU9500001D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
MX9303977A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMPROVEMENT OF THE TRAINING OF A PHARMACOLOGICALLY ACTIVE SUBSTANCE THROUGH THE MUCOUS MEMBRANES OF AN ANIMAL.
US4474798A (en) Pharmaceutical preparation for endermic application
AR030254A1 (en) USE OF A CLOSTRIDIAL NEUROTOXIN COMPONENT COUPLED TO AN OBJECTIVE FRACTION TO PREPARE A PHARMACEUTICAL USE COMPOSITION TO TREAT A BONE TUMOR
ES2195175T3 (en) PHARMACEUTICAL PREPARATION THAT INCLUDES EICOSAPENTAENOIC ACID AND / OR ESTEARIDONIC ACID.
ES2176343T3 (en) HEALING COMPOSITIONS OF TREATMENT OF WOUNDS CAUSED BY THE ACNE THAT CONTAIN A PYRUVAN, AN ANTIOXIDANT AND A MIXTURE OF FATTY ACIDS.
PE799A1 (en) COSMETIC COMPOSITION CONTAINING ANTAGONIST OF NEUROPEPTIDE RECEPTORS AND
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
ATE526956T1 (en) VIRUCIDAL COMPOSITIONS
ATE13286T1 (en) PHARMACEUTICALLY ACTIVE PHENYLIC ACID DERIVATIVES.
ES2099428T3 (en) PHARMACEUTICAL COMPOSITIONS FOR INHALATION.
BR9813811A (en) "pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only a single surfactant"
JP3725557B2 (en) Drugs and cosmetic preparations having anti-acne activity
EP0472531A1 (en) Proanthocyanidol-based composition and its pharmacological application.
ES2032405T3 (en) DERIVATIVES OF VALPROICO AND (E) -2-VALPROENOIC ACIDS, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2053575T3 (en) LIPASES AND LIPASIC EXTRACTS, THEIR PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS.
EP1383540A4 (en) PHARMACEUTICAL METHODS AND COMPOSITIONS FOR HEALING LESIONS
US7993683B2 (en) Compositions for the treatment of chronic degenerative inflammatory conditions
GT199900081A (en) SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS.
FR2461499A1 (en) Topical compsns. with cicatrising activity - contg. bilberry vaccinium myrtillus extract with high anthocyanoside content
AR012546A1 (en) USE OF AT LEAST ONE SELECTED COMPOUND BETWEEN THE GROUP COMPRISING THE SOGAOLS AND THE GINGEROLES FOR THE PREPARATION OF A COMPOSITION DEODORANTE, SOGAOL, GROSS EXTRACT AND PURIFIED EXTRACT CONTAINING THE SOGAOL AND THE DEODANT COMPOSITION.
NO306762B1 (en) Use of lanolin derivatives in conjunction with polyethylene glycol ethers, their mixture and transdermal therapeutic system
CO4790151A1 (en) COMPOSITIONS INCLUDING AN HIV PROTEASE INHIBITOR LIKE VX478 AND A COMPOUND OF VITAMIN E Soluble IN WATER AS VITAMIN E - TPGS
ATE226438T1 (en) BIOACTIVE CONCENTRATE, ITS PRODUCTION PROCESS AND CERTAIN MEDICINAL PRODUCTS WHICH ALSO CONTAIN CHONDROITIN SULFATE
FR2831444A1 (en) Cosmetic or dermatological composition for use as an after-sun product comprises hydrosoluble extracts of buddleia and an anthyllis as well as other herbal extracts
DK225986D0 (en) PHARMACEUTICAL COMPOSITION OF THE TYPE OF PROMEDICATION AND METHOD OF PREPARING THE SAME

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees